Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-549-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity studies (OECD 423) on the structural analogues MI3 and X14DesB30 both resulted in LD50 valus above 2000 mg/kg bw, as no lethaliiy occured at the highest dose levels of 2000 mg/kg bw. Thus, due to close structural similarity to these substances low acute oral toxicity (LD50 > 2000 mg/kg) can be concluded for Insulin aspart precusor as well. The low potential for acute oral toxicity is further supported by the data indicating very low -if any- oral absorption of the substance see section 7.1.1.
Data obtained from an OECD 402 study on MI3 indicate very low acute dermal toxicity potential as LD50 > 2000 mg/kg bw. Thus, due to close structural similarity to MI3 an dermal LD50 > 2000 mg/kg bw can be concluded for Insulin aspart precusor as well. The absence of dermal acute toxicity is further supported by the lack of dermal uptake of the subtance as indicated in 7.1.1.
For further read-across justification see document attached in section 13.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Read-across from acute oral toxicity studies on two closely structural and physicochemical related substances: MI3 (that cannot bind to the insulin receptor) and X14DesB30 (that bind to the insulin receptor). For both substances no lethality was noted at the highest test dose level of 2000 mg/kg/bw.
Thus very low potential for acute toxicity by the oral route can be expected for insulin aspart precursor as well and thus, the criteria for CLP-classification for acute oral toxicity is not met.
For further read-across justification se document attached in section 13. - Executive summary:
Read-across from acute oral toxicity studies on two closely structural and physicochemical related substances: MI3 (that cannot bind to the insulin receptor) and X14DesB30 (that bind to the insulin receptor). For both substances no lethality was noted at the highest test dose level of 2000 mg/kg/bw.
Thus very low potential for acute toxicity by the oral route can be expected for insulin aspart precursor as well and thus, the criteria for CLP-classification for acute oral toxicity is not met.
For further read-across justification se document attached in section 13.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000.03.03 -2000.07.04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL (MI3 dried)
- Source and lot/batch No.of test material: C202483
- Expiration date of the lot/batch: 2001.05.31
- Purity test date: 2001.05.31
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: < -10 degrees Celcius
- Stability under test conditions: NA
- Solubility and stability of the test substance in the solvent/vehicle: Full solubility in vehicle (water)
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: NA
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Purified water (Elgastat purifier used)
- Final preparation of a solid: 100mg/ml MI3 in water
FORM AS APPLIED IN THE TEST (if different from that of starting material): solid disolved in purified water. - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Crl:WI(Glx/BRL/Han)BR)
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 7 - 8 weeks
- Weight at study initiation: 183 -198g (males); 130 - 149g (females)
- Fasting period before study: yes, overnight fasting.
- Housing: Three rats of same sex per cage (suspended stainless steel mesh cage).
- Diet (e.g. ad libitum): ad libitum.
- Water (e.g. ad libitum): ad libitum.
- Acclimation period: 22- 24 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25 degrees Celcuis.
- Humidity (%): 40 - 70%.
- Air changes (per hr): a minimum of 14 air changes per hour.
- Photoperiod (hrs dark / hrs light): 12- / 12 hours
IN-LIFE DATES: From: To: 36 - 38 days. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 100 mg/ml
- Amount of vehicle (if gavage): 20 ml/kg bw.
- Justification for choice of vehicle: MI3 was dispersed in purified water, which is non-toxic in the volume given.
- Lot/batch no. (if required): C202483
- Purity: Pure water (Elgastat purifier)
MAXIMUM DOSE VOLUME APPLIED: 20 ml/kg bw.
DOSAGE PREPARATION (if unusual): NA
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Dose levels were chosen in complience with limits stated in the guidelines - i.e. first dose 2000 mg/kg to three animals of one sex. - Doses:
- 2000 mg/kg bw.
- No. of animals per sex per dose:
- 3 (females) / 3 (males)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Clinical signs:The day of dosing (fist day), one within half an hour of dosing and four times within the first four hours after administration. Twice daily on Days 2, 3 and 4, and once daily from the fifth to the last day of the observation period. Weighing: one day before dosing (day -1), day 1, 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, - Statistics:
- None
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat. (total fraction)
- Mortality:
- There were no deaths following a single oral dose of MI3 of both sexes dosed at 2000 mg/kg.
- Clinical signs:
- There were no clinical signs of reaction to treatment were apparent.
- Body weight:
- All rats gained weight during the first and second week of the observation period.
- Gross pathology:
- No macroscopic changes were observed for animals killed on Day 15.
- Other findings:
- NA
- Interpretation of results:
- GHS criteria not met
- Remarks:
- oral LD50 >2000 mg/kg bw.
- Conclusions:
- The study was conducted to access the acute oral toxicity of MI3 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 423. Groups of three male or female rats were fasted overnight and given a single dose of MI3 oral gavage at a dose level of 2000 mg/kg. All animals were killed at day 15 after dosing. No death, clinical signs or post mortem abnormalities were observed for rats of both sexes after a single oral dose of 2000 mg/kg. The median LD50 of MI3 in rats was found to be > 2000 mg/kg bw.
- Executive summary:
The Study was conducted to access the acute oral toxicity of MI3 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 423, the commission directive 94/54/EEC, Method B1 tris, and the US EPA Health effects test Guidelines OPPTS 870.1100.
The study design provided information for hazard assessment and classification and enables the MI3 to be assigned to one of the four toxicity classes identified in Annex of Commission Directive 93/21/EEC, while severely restricting animal usage.
Groups of three male or female rats were fasted overnight and given a single dose of MI3 oral gavage at a dose level of 2000 mg/kg. The MI3 was dispersed in purified water and dosed at a dose volume of 20 mL/kg. All animals were killed at day 15 after dosing and underwent a full necropsy.
No deaths were observed for rats of both sexes after a single oral dose of 2000 mg/kg. No clinical signs were observed, and all rats (both sexes) gained weight the two weeks following dosing. Necropsy did not reveal any macroscopic abnormalities among the dosed animals.
The median LD50 of MI3 in rats was found to be > 2000 mg/kg bw.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000.03.31 - 2000.07.04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- Principles of method if other than guideline:
- NA
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL (X14DesB30, solid)
- Source and lot/batch No.of test material: X1YIS0201014
- Expiration date of the lot/batch: NA
- Purity test date: 2000.02.18
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: < -70 degrees Celcius
- Stability under test conditions: NA
- Solubility and stability of the test substance in the solvent/vehicle: Full solubility in vehicle (water)
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: NA
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Purified water (Elgastat purifier used)
- Final preparation of a solid: 100mg/ml X14DesB30 in water
FORM AS APPLIED IN THE TEST (if different from that of starting material): solid disolved in purified water. - Species:
- rat
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Crl:WI(Glx/BRL/Han)BR)
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 10 - 11 weeks
- Weight at study initiation: 278 – 336g (males); 180 - 194g (females)
- Fasting period before study: yes, overnight fasting.
- Housing: Three rats of same sex per cage (suspended stainless steel mesh cage).
- Diet (e.g. ad libitum): ad libitum.
- Water (e.g. ad libitum): ad libitum.
- Acclimation period: 14 - 16 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25 degrees Celcuis.
- Humidity (%): 40 - 70%.
- Air changes (per hr): a minimum of 14 air changes per hour.
- Photoperiod (hrs dark / hrs light): 12- / 12 hours
IN-LIFE DATES: From: To: 29 - 31 days. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 100 mg/ml
- Amount of vehicle (if gavage): 20 ml/kg
- Justification for choice of vehicle: MI3 was dispersed in purified water, which is non-toxic in the volume given.
- Lot/batch no. (if required): C202483
- Purity: Pure water (Elgastat purifier)
MAXIMUM DOSE VOLUME APPLIED: 20 ml/kg bw
DOSAGE PREPARATION (if unusual): NA
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Dose levels were chosen in complience with limits stated in the guidelines - i.e. first dose 2000 mg/kg to three animals of one sex. - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 (females) / 3 (males)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Clinical signs: The day of dosing (fist day), one within half an hour of dosing and four times within the first four hours after administration. Twice daily on Days 2, 3 and 4, and once daily from the fifth to the last day of the observation period. Weighing: one day before dosing (day -1), day 1, 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, - Statistics:
- NA
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat. (total fraction)
- Mortality:
- There were no deaths following a single oral dose of X14desB30 of both sexes dosed at 2000 mg/kg.
- Clinical signs:
- There were no clinical signs of reaction to treatment were apparent apart from a single transient observation of pilo-erection for one female one hour after dosing.
- Body weight:
- Two male and three females showed low weight gains or small losses between Day -1 and Day 8. The females continued to show small gains during the second week of the study.
The majority of rats gained weight during the second week of their observation period. - Gross pathology:
- No macroscopic changes were observed for animals killed on Day 15.
- Other findings:
- NA
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The Study was conducted to access the acute oral toxicity of X14DesB30 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 423. Groups of three male or female rats were fasted overnight and given a single dose of X14DesB30 by oral gavage at a dose level of 2000 mg/kg. All animals were killed at day 15 after dosing. No death or post mortem abnormalities were observed for rats of both sexes after a single oral dose of 2000 mg/kg. However, a single transient observation of pilo-erection was observed for one female one hour after dosing. The median lethal dose 50 of X14DesB30 in rats was found to be > 2000 mg/kg bw.
- Executive summary:
The Study was conducted to access the acute oral toxicity of X14DesB30 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 423, the commission directive 94/54/EEC, Method B1 tris, and the US EPA Health effects test Guidelines OPPTS 870.1100.
The study design provided information for hazard assessment and classification and enables the X14DesB30 to be assigned to one of the four toxicity classes identified in Annex of Commission Directive 93/21/EEC, while severely restricting animal usage.
Groups of three male and female rats were fasted overnight and given a single dose of MI3 oral gavage at a dose level of 2000 mg/kg. The X14DesB30 was dispersed in purified water and dosed at a dose volume of 20 mL/kg. All animals were killed at day 15 after dosing and underwent a full necropsy.
No deaths were observed for rats of both sexes after a single oral dose of 2000 mg/kg. No clinical signs were observed, apart from a single transient observation of pilo-erection for one female one hour after dosing. Two male and three females showed low weight gains or small losses the first week. The females continued to show small gains during the second week of the study, although the majority of rats gained weight during the second week of their observation period. Necropsy did not reveal any macroscopic abnormalities among the dosed animals.
The median lethal dose 50 of X14DesB30 in rats was found to be > 2000 mg/kg bw.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat. (total fraction)
- Remarks on result:
- no indication of skin irritation up to the relevant limit dose level
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- No data is available for Insulin aspart precurser (T). Data obtained from an OECD 402 study on MI3 (S2) indicate very low acute dermal toxicity potential as LD50 > 2000 mg/kg bw. Thus, due to close structural similarity to MI3 an dermal LD50 > 2000 mg/kg bw can be concluded for Insulin aspart precusor as well. The absence of dermal acute toxicity is furhter supported by the lack of dermal uptake of the subtance as indicated in 7.1.1.
The criteria for CLP classification for acute dermal toxicity of insulin aspart precursor is not met. - Executive summary:
No data is available for Insulin aspart precurser (T). Data obtained from an OECD 402 study on MI3 indicate very low acute dermal toxicity potential as LD50 > 2000 mg/kg bw. Thus, due to close structural similarity to MI3 an dermal LD50 > 2000 mg/kg bw can be concluded for Insulin aspart precusor as well. The absence of dermal acute toxicity is furhter supported by the lack of dermal uptake of the subtance as indicated in 7.1.1.
The criteria for CLP classification for acute dermal toxicity of insulin aspart precursor is not met.
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000.03.03 - 2000.07.04.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- Storage temperature was < -10 oC. The animals were transferred from another study and had a longer acclimatization period so they approximated to the protocol age range. The changes had no influences on the integrity or the results of the present study
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL (MI3 dried)
- Source and lot/batch No.of test material: C202483
- Expiration date of the lot/batch: 2001.05.31
- Purity test date: 2001.05.31
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: < -10 degrees Celcius
- Stability under test conditions: NA
- Final preparation of a solid: dosed as powder/soild at 2000mg/kg bw
FORM AS APPLIED IN THE TEST (if different from that of starting material): as solid/ powder - Species:
- rat
- Strain:
- Wistar
- Remarks:
- CRL:Han Wist(Glx/BRL)BL)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Crl:WI(Glx/BRL/Han)BR)
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 7 - 8 weeks
- Weight at study initiation: 188 -208g (males); 137 - 163g (females)
- Fasting period before study: yes, overnight fasting.
- Housing: Three rats of same sex per cage (suspended stainless steel mesh cage).
- Diet (e.g. ad libitum): ad libitum.
- Water (e.g. ad libitum): ad libitum.
- Acclimation period: 22- 24 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25 degrees Celcuis.
- Humidity (%): 30 - 70%.
- Air changes (per hr): a minimum of 14 air changes per hour.
- Photoperiod (hrs dark / hrs light): 12- / 12 hours
IN-LIFE DATES: 31- 38 days. - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- Wetting of the application area with 0.2 mL water before adding MI3 powder
- Details on dermal exposure:
- TEST SITE
- Area of exposure: 5 x 5 cm
- % coverage: 10% of the total body surface
- Type of wrap if used: Semi occlusive
REMOVAL OF TEST SUBSTANCE
- Washing (if done): brushed and swabbed with moist cotton wool
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Concentration (if solution): NA
- Constant volume or concentration used: NA
- For solids, paste formed: no
VEHICLE
Not used, application area moistened with water before application of powder. - Duration of exposure:
- 24 hours.
- Doses:
- single dose of 2000 mg/kg bw.
- No. of animals per sex per dose:
- 2 female rats (Preliminary study) and 5 males and 5 females (main study)
- Control animals:
- no
- Details on study design:
- Duration of observation period following administration: 8 days (preliminary study) 14 days (main study)
- Frequency of observations and weighing:
Clinical signs:The day of dosing (fist day), once within half an hour of dosing and four times within the first four hours after administration. Twice daily on Days 2, 3 and 4, and once daily from the fifth to the last day of the observation period. Weighing: one day before dosing (day -1), day 1, 8 and 15.
Dermal reactions were recorded from day 2 of exposure and similar to that for clinical signs.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, - Statistics:
- NA
- Preliminary study:
- Yes: Two female rats dosed at 2000 mg/kg bw. Based on the results these investigations the limie dose level was selected for the main study. Since no compound-related motality occured in the preliminary test, a group of five male and female rats was subjected to a single dermal application of MI3 at 2000 mg/kg bw.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat. (total fraction)
- Remarks on result:
- no indication of skin irritation up to the relevant limit dose level
- Mortality:
- No mortality was observed neither in the preliminary study nor the main study.
- Clinical signs:
- - No signs in the preliminary study.
- Three incidence of anogenital soiling for 3 female rats at day 2, recovery at day 3. No dermal reactions both sex. - Body weight:
- all rats gained weight during the first and second week.
- Gross pathology:
- One male and female rat with slight pelvic dilatation of one kidney.
- Other findings:
- NA
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The Study was conducted to access the acute dermal toxicity of MI3 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 402. In a preliminary study two female rats and in the main study groups of five male and female rats were given a single dose of MI3 at a dose level of 2000 mg/kg bw. All animals were killed at day 8 (preliminary study) or day 15 (main study) after dosing. No death were observed, in the main study transient anogenital soiling was observed among three female rats, and one male and one female rat had slight pelvic dilatation of one kidney. The median LD50 of MI3 in rats was found to be > 2000 mg/kg bw.
- Executive summary:
The Study was conducted to access the acute dermal toxicity of MI3 given as single dose to a small group of rats of both sex. The study was designed in accordance with OECD guideline method 402, the commission directive 92/69/EEC, Method B3, and the US EPA Health effects test Guidelines OPPTS 870.1200.
In the preliminary study two female rats had undiluted MI3 applied to the dorsa at a dose level of 2000 mg/kg bw. In the main study, groups of five male and female rats were given a single topical application of MI3 at a dose level of 2000 mg/kg bw to the dorsum with a semi occlusive bandage covering the dose site for 24 hours. Animals of the preliminary study were killed at day 8, while animals of the main study were killed at day 15. All animals underwent a full necropsy.
Weight gain was recorded among all animals during the study period. In the preliminary study, no death or macroscopic changes were evident 8 days after dosing. In the main study, transient anogenital soiling was observed among three female rats on day 2 with recovery on day 3. On day 15 one male and one female rat had slight pelvic dilatation of one kidney.
The median LD50 of MI3 in rats was found to be > 2000 mg/kg bw.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- mg/kg bw
Additional information
Justification for classification or non-classification
Low acute ptoxic potential is concluded for Insulin aspart precursor as oral and dermal LD50 values were concluded to be above 2000 mg/kg bw. Thus, Insulin aspart precusor is not to be classified for acute oral - or dermal - toxicity according to the CLP-classification criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.